You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: August 2020 to June 2025

AbstractFullPdf
Aug 2020394394106
Sep 2020335335130
Oct 2020818123
Nov 2020606032
Dec 2020464620
Jan 2021575723
Feb 2021454510
Mar 2021626221
Apr 2021707017
May 2021302919
Jun 2021404017
Jul 2021585822
Aug 2021454516
Sep 2021414117
Oct 2021444429
Nov 2021484830
Dec 2021666716
Jan 2022828315
Feb 2022383814
Mar 2022788544
Apr 2022607428
May 2022565715
Jun 2022687325
Jul 2022515122
Aug 2022666620
Sep 2022707218
Oct 2022525624
Nov 202262638
Dec 202226266
Jan 202337376
Feb 2023565612
Mar 2023313230
Apr 2023272814
May 2023454517
Jun 202326268
Jul 2023293019
Aug 202314146
Sep 202316165
Oct 2023222212
Nov 2023313214
Dec 202323236
Jan 2024292918
Feb 2024384016
Mar 2024394132
Apr 2024454424
May 2024404018
Jun 202441419
Jul 2024505121
Aug 2024404113
Sep 2024273013
Oct 2024656516
Nov 202411311721
Dec 2024454719
Jan 2025515122
Feb 2025494934
Mar 2025424219
Apr 2025696925
May 2025959519
Jun 2025434317
Total350935621292